Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety of MY008211A in PNH
NCT06933914Phase 3Recruiting
- Sponsor
- Wuhan Createrna Science and Technology Co., Ltd.
- Start
- Nov 2024
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of MY-008 in paroxysmal nocturnal hemoglobinuria (PNH), sponsored by Wuhan Createrna Science and Technology Co., Ltd. Primary endpoint: Proportion of participants with adverse events, safety laboratory parameters, vital signs, ECG at 100 weeks. Started Nov 2024; status: recruiting.
02
Drugs
MY-008
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT06933914.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06933914.